Develops drugs for cancer and immunological diseases.
Dec 2025Revenue $549M/yrExpenses $588M/yr
No trendCash runway over 10 years from Dec 2025
Figures by year
When will HUTCHMED (China) be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $549M and expenses $588M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $549M | $588M | −$39.2M |
| Dec 2024 | $630M | $674M | −$43.7M |
| Dec 2023 | $838M | $820M | $18.4M |
| Dec 2022 | $426M | $834M | −$408M |
| Dec 2021 | $356M | $684M | −$328M |
| Dec 2020 | $228M | $425M | −$197M |
| Dec 2019 | $205M | $351M | −$146M |
| Dec 2018 | $214M | $307M | −$92.6M |
| Dec 2017 | $241M | $295M | −$53.4M |
| Dec 2016 | $216M | $263M | −$46.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.